Breaking News, Collaborations & Alliances

Santen Begins Trials with Oakwood Technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Santen Pharmaceutical Co., Ltd., of Osaka, Japan has begun Phase I/IIa trials of DE-102, its steroidal treatment for macular edema, employing Oakwood Laboratories’ Chroniject™ sustained release delivery technology. The product’s microsphere formulation and its sterile filling was accomplished at Oakwood’s Cleveland manufacturing facility. “Oakwood is very pleased to have been able to solve some difficult technical issues in order to bring this product to commercial ma...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters